2070009-58-2
2070009-58-2 结构式
基本信息
GDC-0994 HCl
GDC-0994 (hydrochloride)
Ravoxertinib hydrochloride
RAVOXERTINIB HYDROCHLORIDE (GDC-0994 HYDROCHLORIDE)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/12/22 | HY-15947A | CS-2072 Ravoxertinib hydrochloride | 2070009-58-2 | 2mg | 1000元 |
| 2025/12/22 | HY-15947A | CS-2072 Ravoxertinib hydrochloride | 2070009-58-2 | 5mg | 1500元 |
| 2025/12/22 | HY-15947A | CS-2072 Ravoxertinib hydrochloride | 2070009-58-2 | 10mM * 1mLin DMSO | 1575元 |
常见问题列表
|
ERK2 3.1 nM (IC 50 ) |
ERK1 6.1 nM (IC 50 ) |
p-RSK 12 nM (IC 50 ) |
Ravoxertinib also inhibits p90RSK with IC
50
of 12 nM.
Ravoxertinib is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively.
Ravoxertinib (GDC0994; 50 nM, 0.5 µM, and 5 µM; 48 hours) decreases the viability of lung adenocarcinoma cell lines (A549, HCC827, HCC4006).
In CD-1 mice, a 10 mg/kg oral dose of Ravoxertinib is sufficient to achieve the desired target coverage for at least 8 h. Daily, oral dosing of Ravoxertinib results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice.